A Phase 2 interventional study of Abatacept and placebo in Arthritis, Rheumatoid, sponsored by Bristol-Myers Squibb. Completed at 48 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-07.
Sponsored by Bristol-Myers Squibb · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 41st largest by enrollment, is one of 4 that started in 2005, is one of 9 in phase 2, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 45th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2005, is one of 10 in phase 2, and was the 5th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison to placebo. High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-CCP2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Abatacept
Drug: placebo
solution, intravenous injection, monthly, 169 days weight based: \<60 kg = 500 mg 60 to 100 kg = 750 mg \>100 kg = 1 g
Also known as: Orencia
solution, intravenous injection, 0 mg, monthly, 169 days
Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy
ARA criteria is a 7-item tool for RA classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting primary endpoint also.
Time frame: 12 months
Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy
ARA criteria is a 7-item tool for classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.
Time frame: 24 months
Number of Participants With Undifferentiated Inflammatory Arthritis (UA) Who Develop Another Rheumatic Disease
Clinical diagnosis of other rheumatic diseases at 12 and 24 months. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.
Time frame: 12 months, 24 months
Change From Baseline in Radiographic Erosion and Joint Space Narrowing Score at 6 Months, 12 Months, and 24 Months
Mean change from baseline using the Genant-Modified Sharp Score. Erosion score=assessment of 14 sites in each hand and wrist + 6 joints in each foot, using an 8-point scale from 0 (no erosions) to 3.5 (erosions of 100% or articular surfaces). Joint score= assessment of 13 sites in each wrist and hand + 6 sites in each foot using a 9-point scale from 0 (normal) to 4.0 (definite ankylosis). As-observed data. Change from Baseline=postbaseline score at timepoint (6 or 12 or 24 months) minus baseline score; a lower value signifies improvement.
Time frame: Baseline, 6 months, 12 months, 24 months
Change From Baseline in Total Erosion, Edema, Synovitis Scores at 6 Months, 12 Months, and 24 Months
Mean change from baseline. Degree of synovitis and structural joint damage (erosion, edema) of the carpal and metacarpophalangeal joints, as measured by magnetic resonance imaging (MRI) scores using the European League Against Rheumatism (EULAR)-Outcome Measures in Rheumatology Clinical Trials (OMERACT) assessment. Edema scale=0 (no bone involved) to 3 (67% to 100% of bone involved). Synovitis scale=0 (normal) and 1-3 (mild, moderate, severe. Bone erosion scale=0 (0% of bone involved) to 10 (91% to 100% of bone involved). Change from baseline=postbaseline score at timepoint - baseline score.
Time frame: Baseline, 6 months, 12 months, 24 months
Number of Participants With Persistent Symptomatic Clinical Synovitis
Synovitis, assessed by clinical signs and symptoms
Time frame: 6, 12, and 24 months
Short Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) Scores - Mean Change From Baseline
SF-36, a 36-item instrument that covers 8 quality of life domains, which were used to derive the physical and mental component summary scores, which ranged from 0 to 100, with higher scores indicating a better quality of life. Change from baseline=postbaseline - baseline value; a higher value signifies improvement.
Time frame: 6 months, 12 months, 24 months
Change From Baseline in Cytokine Levels and Second Generation Anti-cyclic Citrullinated Peptide (Anti-CCP2) Antibodies at 6 Months, 12 Months, and 24 Months
To assess pharmacodynamic effect of abatacept on serum levels of autoantibodies, mean change from baseline in cytokines (interleukin-6 \[IL-6\], interleukin-1B \[IL-1B\], tumor necrosis factor Alpha \[TNF-Alpha\], Matrix Metalloproteinase 3T \[MMP3T\], and anti-CCP2), as measured by standard laboratory investigations, were assessed. Change from baseline=postbaseline value at timepoint (6 or 12 or 24 months) minus baseline value; a lower value signifies improvement.
Time frame: Baseline, 6 Months, 12 months, 24 months
Number of Participants With Anti-CCP2 Positive and/or Rheumatoid Factor (RF) Positive Over Time
To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, number of participants with Anti-CCP2 Positive of Rheumatoid Factor (RF) positive
Time frame: Day 1, 6 months, 12 months, 24 months
Frequency of Human Leukocyte Antigen (HLA) Typing
To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, a blood sample was obtained for HLA typing to determine the presence or absence of alleles associated with RA susceptibility and severity (shared epitope alleles HLA-DRB10401 and HLA-DRB10404).
Time frame: Day 1
DAS 28 C Reactive Protein (CRP) Score - Mean Change From Baseline
The DAS 28 (CRP) is a composite of 4 variables: 28 tender joint count, 28 swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Change from Baseline=postbaseline score-baseline score; a lower value signifies improvement.
Time frame: 6 months, 12 months, 24 months
Number of Participants With a DAS 28 (CRP) Score of ≤3.2 (Low Disease Activity) or <2.6 (in Remission)
The DAS 28 (CRP) is a composite of 4 variables: tender joint count, swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Scores for disease activity are defined as low (≤ 3.2) and in remission (\< 2.6).
Time frame: 6 months, 12 months, 24 months
Number of Subjects With Health Assessment Questionnaire (HAQ) Disability Index Response
This questionnaire includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. Higher scores indicate greater dysfunction. HAQ response =improvement of at least 0.3 units from baseline.
Time frame: 6 months, 12 months, 24 months
Overall Safety - Adverse Events (AEs), Serious AEs, and Deaths
AEs were monitored at all scheduled visits of the study drug treatment and observation periods and at the follow-up visits performed 28, 56, and 85 days after the last infusion of study medication for participants who were withdrawn prematurely
Time frame: Throughout the treatment period (6 months)
Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies
Immunogenicity, as measured by the number of positive repsonses for serum levels of abatacept-specific antibodies measured by enzyme-linked immunosorbent assays (ELISA). Postive response for whole molecule assessment was a value of \> 400 and for tip assessment was ≥25.
Time frame: Up to 12 months
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 28 | 28 |
| Completed | 22 | 17 |
| Not completed | 6 | 11 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 3 | 8 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Poor/noncompliance | 1 | 0 |
| Withdrew: Sponsor request | 0 | 1 |
| Withdrew: Exposure to mycobacterium tuberculosis | 0 | 1 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 22 | 17 |
| Completed year 1 of study | 14 | 9 |
| Completed | 7 | 4 |
| Not completed | 15 | 13 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 11 | 12 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Poor/noncompliance | 1 | 0 |
| Withdrew: Relocated | 1 | 0 |
ARA criteria is a 7-item tool for RA classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting primary endpoint also.
| Participants | Abatacept | Placebo |
|---|---|---|
| Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy | 12 | 16 |
ARA criteria is a 7-item tool for classification purposes; a patient is said to have RA (meeting endpoint) if he or she has satisfied at least 4 of the 7 criteria. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.
| Participants | Abatacept | Placebo |
|---|---|---|
| Number of Participants With a Diagnosis of RA by 1987 ARA Criteria and/or Discontinued Due to Lack of Efficacy | 17 | 21 |
Clinical diagnosis of other rheumatic diseases at 12 and 24 months. If a participant discontinued due to lack of efficacy, he/she was regarded as meeting endpoint also.
| Participants | Abatacept | Placebo |
|---|---|---|
| 12 months (n=26; n=24) | 0 | 0 |
| 24 months (n=23; n=24) | 0 | 0 |
Mean change from baseline using the Genant-Modified Sharp Score. Erosion score=assessment of 14 sites in each hand and wrist + 6 joints in each foot, using an 8-point scale from 0 (no erosions) to 3.5 (erosions of 100% or articular surfaces). Joint score= assessment of 13 sites in each wrist and hand + 6 sites in each foot using a 9-point scale from 0 (normal) to 4.0 (definite ankylosis). As-observed data. Change from Baseline=postbaseline score at timepoint (6 or 12 or 24 months) minus baseline score; a lower value signifies improvement.
| units on a scale | Abatacept | Placebo |
|---|---|---|
| Erosion Score 6 months (n=22; n=21) | 0.13 ± 0.09 | 0.46 ± 0.24 |
| Joint Space Narrowing 6 months (n=22; n=21) | 0.00 ± 0.00 | 0.01 ± 0.01 |
| Total Score 6 months (n=22; n=21) | 0.13 ± 0.09 | 0.47 ± 0.24 |
| Erosion Score 12 months (n=17; n=11) | 0.02 ± 0.04 | 0.85 ± 0.39 |
| Joint Space Narrowing 12 months (n=17; n=11) | 0.00 ± 0.00 | 0.26 ± 0.22 |
| Total Score 12 months (n=17; n=11) | 0.02 ± 0.04 | 1.11 ± 0.56 |
| Erosion Score 24 months (n=7; n=3) | 0.04 ± 0.04 | -0.17 ± 0.17 |
| Joint Space Narrowing 24 months (n=7; n=3) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Total Score 24 months (n=7; n=3) | 0.04 ± 0.04 | -0.17 ± 0.17 |
Mean change from baseline. Degree of synovitis and structural joint damage (erosion, edema) of the carpal and metacarpophalangeal joints, as measured by magnetic resonance imaging (MRI) scores using the European League Against Rheumatism (EULAR)-Outcome Measures in Rheumatology Clinical Trials (OMERACT) assessment. Edema scale=0 (no bone involved) to 3 (67% to 100% of bone involved). Synovitis scale=0 (normal) and 1-3 (mild, moderate, severe. Bone erosion scale=0 (0% of bone involved) to 10 (91% to 100% of bone involved). Change from baseline=postbaseline score at timepoint - baseline score.
| units on a scale | Abatacept | Placebo |
|---|---|---|
| Erosion Score at 6 months (n=11; n=10) | 0.45 ± 0.37 | 1.20 ± 1.09 |
| Edema Score at 6 months (n=11; n=10) | -1.64 ± 1.48 | 1.40 ± 1.59 |
| Synovitis Score at 6 months (n=11; n=10) | 0.27 ± 0.56 | 1.60 ± 1.23 |
| Erosion Score at 12 months (n=9; n=6) | 0.00 ± 0.17 | 5.00 ± 3.20 |
| Edema Score at 12 months (n=9; n=6) | 0.22 ± 0.49 | 6.67 ± 4.22 |
| Synovitis Score at 12 months (n=9; n=6) | 0.22 ± 0.22 | 2.33 ± 1.61 |
| Erosion Score at 24 months (n=5; n=2) | 0.80 ± 0.49 | 0.00 ± 0.00 |
| Edema Score at 24 months (n=5; n=2) | 0.20 ± 0.20 | 0.50 ± 0.50 |
| Synovitis Score at 24 months (n=5; n=2) | 0.60 ± 0.60 | 1.50 ± 2.50 |
Synovitis, assessed by clinical signs and symptoms
| Participants | Abatacept | Placebo |
|---|---|---|
| 6 months (n=5; n=12) | 4 | 12 |
| 12 months (n=11; n=7) | 10 | 7 |
| 24 months (n=3; n=2) | 3 | 2 |
SF-36, a 36-item instrument that covers 8 quality of life domains, which were used to derive the physical and mental component summary scores, which ranged from 0 to 100, with higher scores indicating a better quality of life. Change from baseline=postbaseline - baseline value; a higher value signifies improvement.
| units on a scale | Abatacept | Placebo |
|---|---|---|
| PCS, 6 months (n=26; n=20) | 10.23 ± 1.68 | 1.95 ± 1.52 |
| MCS, 6 months (n=26; n=20) | 2.54 ± 1.33 | -0.30 ± 1.29 |
| PCS, 12 months (n=20; n=14) | 3.83 ± 2.38 | -0.81 ± 2.26 |
| MCS, 12 months (n=20; n=14) | 2.50 ± 1.75 | -2.89 ± 2.85 |
| PCS, 24 months (n=7; n=5) | 2.46 ± 3.15 | -2.17 ± 6.44 |
| MCS, 24 months (n=7; n=5) | 3.75 ± 1.99 | -3.30 ± 7.58 |
To assess pharmacodynamic effect of abatacept on serum levels of autoantibodies, mean change from baseline in cytokines (interleukin-6 \[IL-6\], interleukin-1B \[IL-1B\], tumor necrosis factor Alpha \[TNF-Alpha\], Matrix Metalloproteinase 3T \[MMP3T\], and anti-CCP2), as measured by standard laboratory investigations, were assessed. Change from baseline=postbaseline value at timepoint (6 or 12 or 24 months) minus baseline value; a lower value signifies improvement.
| laboratory values | Abatacept | Placebo |
|---|---|---|
| IL6 at 6 months (n=19, n=18) | -4.49 ± 1.78 | 1.08 ± 0.72 |
| IL6 at 12 months (n=13, n=7) | -0.14 ± 1.61 | 6.37 ± 3.81 |
| IL6 at 24 months (n=5, n=3) | -3.44 ± 3.54 | 0.90 ± 1.51 |
| IL1B at 6 months (n=18, n=18) | -0.12 ± 0.07 | -0.09 ± 0.08 |
| IL1B at 12 months (n=13, n=7) | -0.09 ± 0.07 | -0.24 ± 0.21 |
| IL1B at 24 months (n=5, n=1) | 0.20 ± 0.20 | 0.00 ± 0.00 |
| TNF-Alpha at 6 months (n=18, n=18) | -1.70 ± 1.29 | 0.07 ± 0.28 |
| TNF-Alpha at 12 months (n=13, n=7) | -0.50 ± 0.25 | -0.10 ± 0.33 |
| TNF-Alpha at 24 months (n=13, n=7) | -0.82 ± 0.47 | -0.03 ± 0.03 |
| MMP3T at 6 months (n=20, n=19) | -2.29 ± 4.86 | 14.34 ± 9.85 |
| MMP3T at 12 months (n=15, n=9) | -2.55 ± 3.08 | 25.34 ± 14.59 |
| MMP3T at 24 months (n=6, n=3) | 6.73 ± 6.93 | 3.10 ± 3.45 |
| Anti-CCP2 antibodies at 6 months (n=21, n=19) | -94.5 ± 29.49 | 16.32 ± 21.49 |
| Anti-CCP2 antibodies at 12 months (n=14, n=10) | -6.46 ± 48.09 | 149.5 ± 64.38 |
| Anti-CCP2 antibodies at 24 months (n=6, n=3) | 3.43 ± 53.85 | -35.1 ± 55.65 |
To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, number of participants with Anti-CCP2 Positive of Rheumatoid Factor (RF) positive
| Participants | Abatacept | Placebo |
|---|---|---|
| Anti-CCP2 Positive on Day 1 (n=28, n=28) | 28 | 28 |
| Anti-CCP2 Positive at 6 months (n=22, n=19) | 20 | 19 |
| Anti-CCP2 Positive at 12 months (n=15, n=10) | 13 | 10 |
| Anti-CCP2 Positive at 24 months (n=6, n=3) | 5 | 3 |
| RF on Day 1 (n=28, n=28) | 24 | 20 |
| RF at 6 months (n=22, n=20) | 13 | 14 |
| RF at 12 months (n=15, n=10) | 11 | 8 |
| RF at 24 months (n=6, n=3) | 3 | 3 |
To assess the pharmacodynamic effect of abatacept on serum levels of autoantibodies, a blood sample was obtained for HLA typing to determine the presence or absence of alleles associated with RA susceptibility and severity (shared epitope alleles HLA-DRB10401 and HLA-DRB10404).
| participants | Abatacept | Placebo |
|---|---|---|
| Missing | 4 | 7 |
| Undetected | 11 | 10 |
| Detected | 13 | 11 |
The DAS 28 (CRP) is a composite of 4 variables: 28 tender joint count, 28 swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Change from Baseline=postbaseline score-baseline score; a lower value signifies improvement.
| units on a scale | Abatacept | Placebo |
|---|---|---|
| 6 Months (n=20; n=20) | -1.13 ± 0.20 | 0.01 ± 0.26 |
| 12 Months (n=18; n=13) | -0.50 ± 0.22 | -0.05 ± 0.42 |
| 24 Months (n=6; n=4) | -0.33 ± 0.33 | 0.69 ± 1.16 |
The DAS 28 (CRP) is a composite of 4 variables: tender joint count, swollen joint count, CRP, and subject assessment of disease activity measure on a VAS of 100 mm. Scores for disease activity are defined as low (≤ 3.2) and in remission (\< 2.6).
| Participants | Abatacept | Placebo |
|---|---|---|
| ≤3.2 at 6 months (n=21; n=20) | 17 | 9 |
| <2.6 at 6 months (n=21; n=20) | 15 | 7 |
| ≤3.2 at 12 months (n=19; n=13) | 13 | 7 |
| <2.6 at 12 months (n=19; n=13) | 9 | 5 |
| ≤3.2 at 24 months (n=7; n=4) | 5 | 2 |
| <2.6 at 24 months (n=7; n=4) | 4 | 2 |
This questionnaire includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. Higher scores indicate greater dysfunction. HAQ response =improvement of at least 0.3 units from baseline.
| Participants | Abatacept | Placebo |
|---|---|---|
| 6 Months (n=26; n=25) | 16 | 6 |
| 12 months (n=25; n=25) | 9 | 3 |
| 24 months (n=21; n=24) | 3 | 1 |
AEs were monitored at all scheduled visits of the study drug treatment and observation periods and at the follow-up visits performed 28, 56, and 85 days after the last infusion of study medication for participants who were withdrawn prematurely
| Participants | Abatacept | Placebo |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 1 | 1 |
| AEs | 18 | 20 |
| Related AEs | 14 | 10 |
| Discontinued due to AEs | 1 | 1 |
Immunogenicity, as measured by the number of positive repsonses for serum levels of abatacept-specific antibodies measured by enzyme-linked immunosorbent assays (ELISA). Postive response for whole molecule assessment was a value of \> 400 and for tip assessment was ≥25.
| participants | Abatacept |
|---|---|
| Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies | 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-188667 | — | 1/28 (3.6%) | 16/28 (57.1%) |
| Placebo | — | 1/28 (3.6%) | 13/28 (46.4%) |
| Event | BMS-188667 | Placebo |
|---|---|---|
| SCIATICANervous system disorders | 0/28 | 1/28 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/28 | 0/28 |
| Event | BMS-188667 | Placebo |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 4/28 | 3/28 |
| PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/28 | 4/28 |
| HEADACHENervous system disorders | 3/28 | 2/28 |
| GASTROENTERITISInfections and infestations | 0/28 | 3/28 |
| NASOPHARYNGITISInfections and infestations | 3/28 | 2/28 |
| URINARY TRACT INFECTIONInfections and infestations | 2/28 | 3/28 |
| NAUSEAGastrointestinal disorders | 0/28 | 2/28 |
| VOMITINGGastrointestinal disorders | 2/28 | 0/28 |
| CONSTIPATIONGastrointestinal disorders | 0/28 | 2/28 |
| RHINITISInfections and infestations | 0/28 | 2/28 |
| Age, Continuous(years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 44.8 ± 10.9 | 44.7 ± 12.1 | 44.8 ± 11.4 |
| Age, Continuous(years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Median | 43.5 (23.0 to 74.0) | 44.0 (26.0 to 71.0) | 44.0 (23.0 to 74.0) |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 20 | 20 | 40 |
| Male | 8 | 8 | 16 |
| Race/Ethnicity, Customized(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| White | 25 | 23 | 48 |
| Black | 1 | 3 | 4 |
| Asian | 1 | 1 | 2 |
| Other | 1 | 1 | 2 |
| Region of Enrollment(participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| North America | 6 | 5 | 11 |
| South America | 5 | 2 | 7 |
| Europe | 17 | 21 | 38 |
| Months of Undifferentiated Inflammatory Arthritis (UA)(Months) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 8.8 ± 4.2 | 7.1 ± 4.4 | 7.9 ± 4.3 |
| Weight(Kilograms) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 75.9 ± 22.5 | 70.9 ± 13.9 | 73.4 ± 18.7 |
The record gives a start of Feb 2005, a primary completion of May 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept